Gelatinase expression and proteolytic activity in giant-cell arteritis

Annals of the Rheumatic Diseases

Volumn 66, Issue 11, 2007, Pages 1429-1435

  Segarra, Marta ^b   García Martínez, Ana ^b   Sánchez, Montse ^b   Hernández Rodríguez, José ^b   Lozano, Ester ^b   Grau, Josep M ^b   Cid, Maria C ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MESSENGER RNA; PREDNISONE; PROTEIN MMP14; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ARTICLE; BLOOD VESSEL BIOPSY; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GIANT CELL ARTERITIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTIMA; LEUKOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TEMPORAL ARTERY; VASCULAR SMOOTH MUSCLE; ZYMOGRAPHY;

BIOPSY; ENZYME ACTIVATION; GELATINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOCORTICOIDS; HUMANS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; RNA, MESSENGER; TEMPORAL ARTERIES; TEMPORAL ARTERITIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 35648987258     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.068148     Document Type: Article

References (36)

1. Weyand CM, Goronzy JJ. Medium-and-large vessel vasculitis. N Engl J Med 2003;349:160-9.
2. Hernández-Rodríguez J, Villar I, García-Martínez A, Font C, Esteban MJ, Sanmartí R, et al. Histopathologic findings in temporal artery biopsies from 171 patients with giant-cell arteritis (GCA): Relationship with prospectively recorded clinical manifestations. Arthritis Rheum 2005;52(suppl):S222.
3. Esteban MJ, Font C, Hernández-Rodríguez J, Valls-Solé J, Sanmartí R, Cardellach F, García- Martínez A, et al. Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathological findings in a series of twenty-eight patients. Arthritis Rheum 2001;44:1387-95.
4. Cid MC, Cebrián M, Font C, Coll-Vinent B, Hernández-Rodríguez J, Esparza J, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 2000;43:184-94.
5. Cid MC, Hernández-Rodríguez J, Esteban MJ, Cebrián M, Gho YS, Font C, Urbano-Márquez A, Grau JM, Kleinman HK. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002;106:1664-71.
6. Kimmelstiel P, Gilmour MT, Hodges HH. Degeneration of elastic fibers in granulomatous giant cell arteritis (temporal arteritis). AMA Arch Pathol 1952;54:157-68.
7. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005;1755:37-69.
8. Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
9. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG. Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 1991;266:7870-5.
10. Bongartz T, Matteson EL. Large-vessel involvement in giant-cell arteritis. Curr Opin Rheumatol 2006;18:10-7.
11. García-Martínez A, Hernández-Rodríguez J, Segarra M, Cid MC. Prevalence of aortic aneurysm in the follow-up of patient with giant-cell arteritis (GCA). A prospective study. Arthritis Rheum 2005;52(suppl):S222.
12. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625-32.
13. Woessner JF. MMPs and TIMPs - an historical perspective. Mol Biotechnol 2002;22:33-49.
14. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Nechanism of cell surface activation of 72 kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase. J Biol Chem 1995;270:5331-8.
15. Nikkari ST, Hoyhtya M, Isola J, Nikkari T. Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996;149:1427-33.
16. Sorbi D, French DL, Nuovo GJ, Kew RR, Arbeit LA, Gruber BL. Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. Arthritis Rheum 1996;39:1747-53.
17. Tomita T, Imakawa K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in giant cell arteritis: an immunocytochemical study. Pathology 1998;30:40-50.
18. Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest 1994;94:1134-40.
19. Rodríguez-Pla A, Bosch-Gil JA, Rosselló-Urgell J, Huguet-Redecilla P, Stone JH, Vilardell-Tarrés M. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation 2005;112:264-69.
20. Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, Grau JM, Urbano-Márquez A, Colomer D, Kleinman HK, Cid MC. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-2434.
21. Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, Queralt C, Grau JM, Urbano-Márquez A, Palacín A, Colomer D, Cid MC. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004;43:294-301.
22. Esparza J, Vilardell C, Calvo J, Juan M, Vives J, Urbano-Márquez A, et al. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood 1999;94:2754-66.
23. Segarra M, Vilardell C, Matsumoto K, Esparza J, Lozano E, Serra-Pages C, et al. Dual function of focal adhesion kinase in regulating integrin-induced MMP-2 and MMP-9 release by human T lymphoid cells. FASEB J 2005;19:1875-7.
24. Lehti K, Lohi J, Valtanen H, Keski-Oja J. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J 1998;334:345-53.
25. Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006;206:1-8.
26. Dien J, Amin HM, Chiu N, WOng W, Frantz C, Chiu B, et al. Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol 2006;169:633-42.
27. Esparza J, Kruse M, Lee J, Michaud M, Madri JA. MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J 2004;18:1682-91.
28. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002;169:2643-7.
29. Matías-Román S, Gálvez BG, Genís L, Yánez-Mo M, de la Rosa G, Sánchez-Mateos P, Sánchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood 2005;105:3956-64.
30. Parks WL, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617-29.
31. Rittner HL, Kaiser M, Brack A, Szweda LI, Goronzy JJ, Weyand CM. Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999;84:1050-8.
32. Kaiser M, Younge B, Bjornsson J, Goronzy JJ, Weyand CM. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999;155:765-74.
33. Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS, Keating MT, Li DY. A critical role for elastin signaling in vascular morphogenesis and disease. Development 2003;130:411-23.
34. Aljada A, Ghanim H, Mohanty D, Triparthy D, Dandona P. Hydrocortisone suppress intranuclear activation protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinases 2 and 9 (MMP2 and MMP9). J Endocrinol 2001;86:5988-9.
35. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
36. Gewert K, Svenson V, Andersson K, Holst E, Sundler R. Dexamethasone differentially regulates cytokine ttranscription and translation in macrophages responding to bacteria or okadaic acid. Cell Signal 1999;11:665-70.